Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021843 (bowel obstruction)
 9,927 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This phase I/II nonrandomized, open-label study was designed to assess the safety and benefit of sequencing irinotecan (Camptosar, CPT-11) plus paclitaxel (Taxol) immediately after cisplatin (Platinol)/etoposide (VePesid, VP-16) or carboplatin (Paraplatin)/etoposide in patients with extensive small-cell lung cancer (SCLC). Ten patients were evaluable in phase I; all had previously been treated with cisplatin and etoposide, and five of the 10 had also previously received carboplatin and paclitaxel. All 10 patients were given a fixed dose of irinotecan (60 mg/m2) and escalating doses of paclitaxel weekly for 3 weeks. Three patients had grade 4 toxicities, one at the lowest dose level of paclitaxel (15 mg/m2). Two patients had grade 3 toxicities. The dose-limiting toxicity occurred at the 60 mg/m2 paclitaxel dose level, when the performance status of both patients in that group decreased to 60 (Karnofsky scale). Two patients had progressive disease after 1 month of treatment and did not receive cycle 2. Three of seven patients evaluable for response had complete remissions. A fourth patient had resolution of lymphangitic metastases and resolution of a partial small bowel obstruction but did not have measurable disease. The fifth patient had a partial remission. The ongoing phase II portion of the study is restricted to previously untreated patients who will receive at least one cycle of either cisplatin or carboplatin in combination with etoposide followed by irinotecan at 60 mg/m2 and paclitaxel at 50 mg/m2 dosed once weekly for 3 weeks.
 ...
PMID:Phase I/II study of weekly irinotecan and paclitaxel in patients with SCLC. 1098 Dec 93

A 54-year-old man underwent abdominoperineal resection for rectal cancer. Adjuvant chemotherapy was not performed because of stage I cancer. Nine months after the operation, solitary liver metastasis, and elevated CEA and CA19-9, were found during the postoperative work-up. A combination chemotherapy of CPT-11 and UFT-E was performed before scheduled liver resection. 150 mg/m2 of CPT-11 was administered on days 1 and 15. 375 mg/m2/day of UFT-E was divided in half and administered on days 3-7, 10-14, 17-21, and 24-28 as one course of treatment. This regimen was repeated every 5 weeks. The patient had a grade 2 diarrhea and nentropenia during the treatment. Bowel obstruction was also observed after 5 courses of treatment, which required hospitalization. In addition, the liver metastasis had disappeared. There was no evidence of recurrence after 8 months of chemotherapy. It was suggested that CPT-11+UFT-E combination chemotherapy was effective for advanced colorectal cancer.
 ...
PMID:[Case report--Complete response of liver metastasis of rectal cancer after combination chemotherapy of CPT-11 + UFT-E]. 1555 88

We report here a case of recurrent gastric cancer that responded to third-line chemotherapy with CPT-11 and CDDP. The patient was a 61-year-old man with recurrent gastric cancer, who had administered TS-1 for first-line chemotherapy and paclitaxel for second-line chemotherapy. After such therapy, bowel obstruction was revealed due to peritoneal dissemination. The patient underwent third-line chemotherapy with CPT-11 and CDDP after drainage of gastrointestinal juice by nasogastric tube. The treatment schedule for CPT-11 and CDDP therapy consisted of CPT-11 60 mg/m2 div at day 1, day 15 and CDDP 60 mg/m2 div at day 1. It was repeated every 4 weeks. After first administration, the bowel obstruction was improved, so the treatment was continued for 8 months on an outpatient basis. These findings imply that this treatment can be a useful second-line or third-line chemotherapy for unresectable advanced or recurrent gastric cancer.
 ...
PMID:[A case report of bowel obstruction due to peritonitis carcinomatosa using combined administration with CPT-11 and CDDP]. 1604 75

Head and neck metastases from colorectal carcinoma are very rare. We report on a 47-year-old woman who had a vegetating tumor located at the distal sigmoid colon with initial liver metastases. She underwent palliative transverse colostomy to prevent intestinal obstruction. She was then treated with 5-fluorouracil, leucovorin and CPT-11. At the third cycle she presented with toothache and numbness of her upper lip. Computed tomography (CT) of the head and neck showed a gross mass involving the sphenoid sinus, left maxillary sinus, left pterygopalatine plate, pterygopalatine and infratemporal fossa. Histology of the mass revealed metastatic adenocarcinoma which was similar with the primary sigmoid carcinoma. The patient underwent radiotherapy and died 2 months later. Although cranial fossa metastases from colorectal cancer are very rare, the physicians should be aware of this type of metastatic pattern in patients who suffer of toothache, painful mastication or numbness of the lips, especially if decay has not been determined.
 ...
PMID:Infratemporal fossa and maxillary sinus metastases from colorectal cancer: a case report. 1730 65

A 52-year-old male admitted to our hospital for ileus was diagnosed with advanced pancreatic cancer. He was complicated with multiple alimentary tract stenosis (duodenal third portion, ascending portion and splenic-flexure portion of colon) due to intraabdominal spread of malignancies. The self-expandable metal stent was successfully placed in each stenotic portion with being effectively decompressed of his intestinal obstruction by the procedure of percutaneous transesophageal gastro-tubing (PTEG). These treatments improved his symptoms to ingest orally in addition to the tube feeding per PTEG. Furthermore, he has been receiving adjuvant chemotherapy with GEM, S-1, and CPT-11 for 9 months at outpatient department. We concluded a combined procedure of self-expandable stent and PTEG was useful palliative treatment in malignant gastrointestinal obstruction of advanced pancreatic cancer.
 ...
PMID:[A case of advanced pancreatic cancer treated successfully with self-expandable stent, PTEG and chemotherapy]. 1821 79

A 74-year-old man who had undergone distal gastrectomy was diagnosed with metastasis to the spleen and transverse colon 27 months after the operation, and 6 courses of combination therapy with S-1 and cisplatin (CDDP) were administered. However, both lesions showed progressive disease (PD) after chemotherapy. Massive gastrointestinal hemorrhage from colon metastases was observed following the administration of irinotecan(CPT-11). Therefore, total remnant gastrectomy, splenectomy, and partial transverse colectomy were performed via the laparoscopic approach. Chemotherapy using paclitaxe(l PTX) was initiated after surgery. However, bowel obstruction due to intestinal metastatic lesions developed after 4 courses of PTX therapy, and right hemicolectomy and partial resection of the small intestine were performed laparoscopically. Although combination therapy of capecitabine and CDDP were administered, the patient died 28 months after the diagnosis of recurrent disease. Typically, surgical intervention is rarely effective in cases of recurrent disease from gastric cancer. However, a favorable quality of life was obtained in the case of our patient with aggressive multimodal therapy that included laparoscopic surgery.
...
PMID:[A case of repeated postoperative recurrence of gastric cancer treated via laparoscopic approach]. 2439 51

The patient was 55-year-old woman, undergoing Hartmann operation by the sigmoid colon diverticulum perforation, 2 years later visited our hospital with abdominal pain. Although lower endoscopy and histological examination could not be performed due to stoma stenosis, we diagnosed cecal carcinoma, liver metastasis, distant lymph node metastasis from CT and PET-CT, CapeOX plus Bmabtherapy and IRIS plus Bmabtherapy were performed. After that, repeated intestinal obstruction due to exacerbated stoma stenosis, metastatic lesion increased in CT examination, furthermore the patient had hope of stoma closure, we decided to resect the primacy tumor, performed subtotal colonectomy and stoma closure. Pathological diagnosis revealed RAS wild type. After surgery, Pmabplus CPT-11 therapy was performed and the metastatic lesion was temporarily shrunk but re-exacerbated, the patient died 2 years 2 months after the first treatment started, 7 months after the primary tumor resection. In the treatment of colorectal cancer, when metastatic lesion is unresectable, chemotherapy is often carried out except when the primary tumor is symptomatic. In our case, although the primary tumor was asymptomatic, an intestinal obstruction due to stoma stenosis was developed and it was necessary to examine whether to use anti-EGFR antibody drugs, therefore we performed operation.
 ...
PMID:[A Case of Surgery after Chemotherapy for Cecal Cancer with Onset of the Stenosis of the Colostomy]. 2948 45